Cantor Fitzgerald Maintains Overweight on Marinus Pharma, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Marinus Pharma but lowers the price target from $13 to $4.
October 25, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Marinus Pharma but significantly lowered the price target from $13 to $4, indicating a more cautious outlook.
The significant reduction in the price target from $13 to $4 suggests a more cautious outlook on Marinus Pharma's future performance, which could lead to a negative short-term impact on the stock price. However, the maintained Overweight rating indicates some level of confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100